{"id":57589,"date":"2026-05-25T17:56:00","date_gmt":"2026-05-25T10:56:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=57589"},"modified":"2026-05-25T17:56:00","modified_gmt":"2026-05-25T10:56:00","slug":"menarini-group-announces-new-data-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=57589","title":{"rendered":"Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2296569\/5986058\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.\u00a0\n<p><\/p><\/i><\/li>\n<li><i>Data from the\u00a0elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in combination settings in mBC, along with updates from the <\/i><i>elacestrant clinical development program, including its potential role as a monotherapy option in adjuvant breast cancer.\n<p><\/p><\/i><\/li>\n<li><i>Stemline&#8217;s partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in myelofibrosis<\/i><\/li>\n<\/ul>\n<p class=\"prntac\">&#8220;FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY&#8221;<\/p>\n<p><span class=\"legendSpanClass\">FLORENCE, Italy and NEW YORK<\/span>, <span class=\"legendSpanClass\">May 25, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0The Menarini Group (&#8220;Menarini&#8221;), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (&#8220;Stemline&#8221;), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and tagraxofusp\u00a0will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<p>New data exploring the safety and preliminary efficacy of elacestrant\u00a0in combination\u00a0with capivasertib in patients with ER+\/HER2- PI3K\/AKT\/PTEN- pathway altered metastatic breast cancer (mBC)\u00a0from the phase 1\/2 ELEVATE\u00a0study will be presented. Additional details on ongoing studies of elacestrant in combination, in the advanced setting, will be shared: ADELA (pivotal phase 3 combination with everolimus);\u00a0ELECTRA (phase 1b\/2 combination with abemaciclib in patients with brain metastases); and CAPELA (phase 2 combination with\u00a0capecitabine).\u00a0Lastly,\u00a0an update from the ELEGANT study, exploring elacestrant as adjuvant treatment in node-positive early breast cancer with high risk of recurrence,\u00a0will be presented\u00a0at the\u00a0congress.<\/p>\n<p>Also accepted for presentation is new phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), which will be presented by Naveen Pemmaraju, MD, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Additionally, Stemline&#8217;s partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in JAKi na\u00efve patients with myelofibrosis (MF). Selinexor is marketed in the U.S. by Karyopharm Therapeutics, and in the EU by Stemline.<\/p>\n<p>&#8220;The extensive oncology data that will be presented, encompassing both solid tumors and hematologic malignancies, highlights our dedication to tackling the most difficult-to-treat cancers with high unmet needs,&#8221; said\u00a0Elcin Barker Ergun, CEO of the Menarini Group. &#8220;Our focus remains on accelerating innovation to provide transformational, targeted therapies that offer meaningful advances to patients and the healthcare communities dedicated to their care.&#8221;<\/p>\n<p>See below for full details of upcoming presentations:<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnrbrb1 prnbbbs prnsblb1\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Lead Author<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Abstract Title and ID<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Presentation <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Details<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Elacestrant<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Wassim McHayleh <\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Elacestrant in combination with capivasertib in patients with <br \/>ER+\/HER2- advanced breast cancer: Update from ELEVATE, a <br \/>phase 1b\/2 open-label, umbrella study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: 1098<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 212<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Aditya Bardia<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ELEGANT: Elacestrant versus standard endocrine therapy in <br \/>women and men with node-positive, estrogen receptor-positive <br \/>(ER+), HER2-negative (HER2-), early breast cancer with high risk of <br \/>recurrence in a global, multicenter, randomized, open-label phase 3 study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1153<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 262a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Antonio Llombart-<br \/>Cussac<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ADELA: A double-blind, placebo-controlled, randomized phase 3 <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">trial of\u00a0elacestrant + everolimus versus elacestrant + placebo in <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">ER+\/HER2- advanced breast cancer patients with ESR1-mutated <br \/>tumors progressing on endocrine therapy + CDK4\/6i*<sup>#<\/sup><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1154<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 262b<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Nuhad Ibrahim<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ELECTRA: An open-label multicenter, phase 1b\/2 study of <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">elacestrant in combination with abemaciclib in patients with brain <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">metastasis from ER+\/HER2- breast cancer<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1155<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 263a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Kristina Fanucci<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">CAPELA: A phase II multicenter open-label randomized study of <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">capecitabine in combination with elacestrant versus capecitabine <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">alone in advanced estrogen receptor (ER)\u2013positive breast cancer <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(TBCRC 070)*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1156<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 263b<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Tagraxofusp<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Naveen Pemmaraju\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">A Phase II Trial of Tagraxofusp, Hyper-CVAD, and Venetoclax for <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Patients with Newly Diagnosed or Relapsed\/Refractory\u00a0BPDCN*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract:\u00a06502<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral\u00a0Presentation<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">June 2, 2026; 10:09 \u2013 10:21 am CT<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Selinexor <\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">John Mascarenhas\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Selinexor plus ruxolitinib in JAK inhibitor\u2013na\u00efve myelofibrosis: <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Phase 3 SENTRY trial*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: LBA6500\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral Presentation<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">June 2, 2026; 9:45 am \u2013 12:45 pm CT<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>*Denotes investigator sponsored research or collaborative research<br \/><\/i><i>#The\u00a0ADELA\u00a0study is a pivotal study co-sponsored with\u00a0MEDSIR<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>About The Elacestrant Clinical Development Program<br \/><\/b>Elacestrant is also being investigated in several company-sponsored clinical trials in breast cancer disease, alone or in combination with other therapies. ELEGANT\u00a0(<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06492616\" target=\"_blank\" rel=\"nofollow\">NCT06492616<\/a>) is a phase 3 trial\u00a0evaluating the effectiveness of elacestrant versus standard endocrine therapy in women and men with node-positive, ER+, HER2- early breast cancer with high risk of recurrence. ADELA (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06382948?cond=Breast%20Cancer&amp;term=Elacestrant%20&amp;limit=25&amp;page=1&amp;rank=12\" target=\"_blank\" rel=\"nofollow\">NCT06382948<\/a>) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. ELEVATE (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05563220\" target=\"_blank\" rel=\"nofollow\">NCT05563220<\/a>) is a phase 1b\/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA\u00a0(<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05386108\" target=\"_blank\" rel=\"nofollow\">NCT05386108<\/a>) is an open-label phase 1b\/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05596409\" target=\"_blank\" rel=\"nofollow\">NCT05596409<\/a>) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced\/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4\/6 inhibitors in the metastatic setting. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc.\u00a0<br \/>at <a href=\"mailto:adverseevents@menarinistemline.com\" rel=\"nofollow\">adverseevents@menarinistemline.com<\/a>.\u00a0 All of the relevant information can be found at <a href=\"https:\/\/stemline.com\/contact\/\" rel=\"nofollow\">https:\/\/stemline.com\/contact\/<\/a><\/p>\n<p>Full prescribing information for elacestrant can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info<\/a><\/p>\n<p>Full prescribing information for selinexor can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio#product-info<\/a><\/p>\n<p>Full prescribing information for tagraxofusp can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elzonris#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elzonris#product-info<\/a>\u00a0<\/p>\n<p><b>About The Menarini Group<br \/><\/b>The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5.5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini&#8217;s products are available in 140 countries worldwide. For further information, please visit\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow\">www.menarini.com<\/a>.<\/p>\n<p><b>About Stemline Therapeutics Inc.<\/b><br \/>Stemline Therapeutics, Inc. (&#8220;Stemline&#8221;), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, <i>ESR1<\/i>-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2296569\/5986058\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.\u00a0\n<\/p>\n<p><\/i><\/li>\n<li><i>Data from the\u00a0elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in combination settings in mBC, along with updates from the <\/i><i>elacestrant clinical development program, including its potential role as a monotherapy option in adjuvant breast cancer.\n<\/p>\n<p><\/i><\/li>\n<li><i>Stemline&#8217;s partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in myelofibrosis<\/i><\/li>\n<\/ul>\n<p class=\"prntac\">&#8220;FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY&#8221;<\/p>\n<p><span class=\"legendSpanClass\">FLORENCE, Italy and NEW YORK<\/span>, <span class=\"legendSpanClass\">May 25, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0The Menarini Group (&#8220;Menarini&#8221;), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (&#8220;Stemline&#8221;), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and tagraxofusp\u00a0will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<p>New data exploring the safety and preliminary efficacy of elacestrant\u00a0in combination\u00a0with capivasertib in patients with ER+\/HER2- PI3K\/AKT\/PTEN- pathway altered metastatic breast cancer (mBC)\u00a0from the phase 1\/2 ELEVATE\u00a0study will be presented. Additional details on ongoing studies of elacestrant in combination, in the advanced setting, will be shared: ADELA (pivotal phase 3 combination with everolimus);\u00a0ELECTRA (phase 1b\/2 combination with abemaciclib in patients with brain metastases); and CAPELA (phase 2 combination with\u00a0capecitabine).\u00a0Lastly,\u00a0an update from the ELEGANT study, exploring elacestrant as adjuvant treatment in node-positive early breast cancer with high risk of recurrence,\u00a0will be presented\u00a0at the\u00a0congress.<\/p>\n<p>Also accepted for presentation is new phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), which will be presented by Naveen Pemmaraju, MD, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Additionally, Stemline&#8217;s partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in JAKi na\u00efve patients with myelofibrosis (MF). Selinexor is marketed in the U.S. by Karyopharm Therapeutics, and in the EU by Stemline.<\/p>\n<p>&#8220;The extensive oncology data that will be presented, encompassing both solid tumors and hematologic malignancies, highlights our dedication to tackling the most difficult-to-treat cancers with high unmet needs,&#8221; said\u00a0Elcin Barker Ergun, CEO of the Menarini Group. &#8220;Our focus remains on accelerating innovation to provide transformational, targeted therapies that offer meaningful advances to patients and the healthcare communities dedicated to their care.&#8221;<\/p>\n<p>See below for full details of upcoming presentations:<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnrbrb1 prnbbbs prnsblb1\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Lead Author<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Abstract Title and ID<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Presentation <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Details<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Elacestrant<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Wassim McHayleh <\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Elacestrant in combination with capivasertib in patients with <br \/>ER+\/HER2- advanced breast cancer: Update from ELEVATE, a <br \/>phase 1b\/2 open-label, umbrella study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: 1098<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 212<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Aditya Bardia<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ELEGANT: Elacestrant versus standard endocrine therapy in <br \/>women and men with node-positive, estrogen receptor-positive <br \/>(ER+), HER2-negative (HER2-), early breast cancer with high risk of <br \/>recurrence in a global, multicenter, randomized, open-label phase 3 study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1153<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 262a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Antonio Llombart-<br \/>Cussac<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ADELA: A double-blind, placebo-controlled, randomized phase 3 <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">trial of\u00a0elacestrant + everolimus versus elacestrant + placebo in <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">ER+\/HER2- advanced breast cancer patients with ESR1-mutated <br \/>tumors progressing on endocrine therapy + CDK4\/6i*<sup>#<\/sup><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1154<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 262b<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Nuhad Ibrahim<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ELECTRA: An open-label multicenter, phase 1b\/2 study of <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">elacestrant in combination with abemaciclib in patients with brain <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">metastasis from ER+\/HER2- breast cancer<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1155<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 263a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Kristina Fanucci<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">CAPELA: A phase II multicenter open-label randomized study of <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">capecitabine in combination with elacestrant versus capecitabine <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">alone in advanced estrogen receptor (ER)\u2013positive breast cancer <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">(TBCRC 070)*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: TPS1156<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">June 1, 2026; 1:30 \u2013 4:30 PM CT\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster Board 263b<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Tagraxofusp<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Naveen Pemmaraju\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">A Phase II Trial of Tagraxofusp, Hyper-CVAD, and Venetoclax for <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Patients with Newly Diagnosed or Relapsed\/Refractory\u00a0BPDCN*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract:\u00a06502<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral\u00a0Presentation<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">June 2, 2026; 10:09 \u2013 10:21 am CT<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Selinexor <\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">John Mascarenhas\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Selinexor plus ruxolitinib in JAK inhibitor\u2013na\u00efve myelofibrosis: <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Phase 3 SENTRY trial*<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract: LBA6500\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral Presentation<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">June 2, 2026; 9:45 am \u2013 12:45 pm CT<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvam prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>*Denotes investigator sponsored research or collaborative research<br \/><\/i><i>#The\u00a0ADELA\u00a0study is a pivotal study co-sponsored with\u00a0MEDSIR<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><b>About The Elacestrant Clinical Development Program<br \/><\/b>Elacestrant is also being investigated in several company-sponsored clinical trials in breast cancer disease, alone or in combination with other therapies. ELEGANT\u00a0(<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06492616\" target=\"_blank\" rel=\"nofollow\">NCT06492616<\/a>) is a phase 3 trial\u00a0evaluating the effectiveness of elacestrant versus standard endocrine therapy in women and men with node-positive, ER+, HER2- early breast cancer with high risk of recurrence. ADELA (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06382948?cond=Breast%20Cancer&amp;term=Elacestrant%20&amp;limit=25&amp;page=1&amp;rank=12\" target=\"_blank\" rel=\"nofollow\">NCT06382948<\/a>) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. ELEVATE (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05563220\" target=\"_blank\" rel=\"nofollow\">NCT05563220<\/a>) is a phase 1b\/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA\u00a0(<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05386108\" target=\"_blank\" rel=\"nofollow\">NCT05386108<\/a>) is an open-label phase 1b\/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05596409\" target=\"_blank\" rel=\"nofollow\">NCT05596409<\/a>) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced\/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4\/6 inhibitors in the metastatic setting. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc.\u00a0<br \/>at <a href=\"mailto:adverseevents@menarinistemline.com\" rel=\"nofollow\">adverseevents@menarinistemline.com<\/a>.\u00a0 All of the relevant information can be found at <a href=\"https:\/\/stemline.com\/contact\/\" rel=\"nofollow\">https:\/\/stemline.com\/contact\/<\/a><\/p>\n<p>Full prescribing information for elacestrant can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info<\/a><\/p>\n<p>Full prescribing information for selinexor can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio#product-info<\/a><\/p>\n<p>Full prescribing information for tagraxofusp can be found at <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elzonris#product-info\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elzonris#product-info<\/a>\u00a0<\/p>\n<p><b>About The Menarini Group<br \/><\/b>The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5.5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini&#8217;s products are available in 140 countries worldwide. For further information, please visit\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow\">www.menarini.com<\/a>.<\/p>\n<p><b>About Stemline Therapeutics Inc.<\/b><br \/>Stemline Therapeutics, Inc. (&#8220;Stemline&#8221;), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, <i>ESR1<\/i>-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-57589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/57589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57589"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/57589\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}